Diagnosis of Zika Virus Infection by Peptide Array and Enzyme-Linked Immunosorbent Assay
Creators: name: Mishra, Nischay
name: Caciula, Adrian
name: Price, Adam R.
name: Thakkar, Riddhi K.
name: Ng, James P.
name: Chauhan, Lokendra V.
name: Jain, Komal
name: Che, Xiaoyu
name: Espinosa, Diego A.
name: Cruz, Magelda Montoya
name: Balmaseda, Angel
name: Sullivan, Eric H.
name: Patel, Jigar J.
name: Jarman, Richard G.
name: Rakeman, Jennifer L.
name: Egan, Christina T.
name: Reusken, Chantal B. E. M.
name: Koopmans, Marion P. G.
name: Harris, Eva
name: Tokarz, Rafal
name: Briese, Thomas
name: Lipkin, W. Ian
Publisher: name: Columbia University
Year: 2018
Subjects: subject: Zika virus
subject: Zika virus infection
subject: Serology
subject: Emerging infectious diseases
subject: Microbiology
subject: FOS: Biological sciences

description: Zika virus (ZIKV) is implicated in fetal stillbirth, microcephaly, intracranial calcifications, and ocular anomalies following vertical transmission from infected mothers. In adults, infection may trigger autoimmune inflammatory polyneuropathy. Transmission most commonly follows the bite of infected Aedes mosquitoes but may also occur through sexual intercourse or receipt of blood products. Definitive diagnosis through detection of viral RNA is possible in serum or plasma within 10 days of disease onset, in whole blood within 3 weeks of onset, and in semen for up to 3 months. Serological diagnosis is nonetheless critical because few patients have access to molecular diagnostics during the acute phase of infection and infection may be associated with only mild or inapparent disease that does not prompt molecular testing. Serological diagnosis is confounded by cross-reactivity of immune sera with other flaviviruses endemic in the areas where ZIKV has recently emerged. Accordingly, we built a high-density microarray comprising nonredundant 12-mer peptides that tile, with one-residue overlap, the proteomes of Zika, dengue, yellow fever, West Nile, Ilheus, Oropouche, and chikungunya viruses. Serological analysis enabled discovery of a ZIKV NS2B 20-residue peptide that had high sensitivity (96.0%) and specificity (95.9%) versus natural infection with or vaccination against dengue, chikungunya, yellow fever, West Nile, tick-borne encephalitis, or Japanese encephalitis virus in a microarray assay and an enzyme-linked immunosorbent assay (ELISA) of early-convalescent-phase sera (2 to 3 weeks after onset of symptomatic infection).

IMPORTANCE The emergence of Zika virus (ZIKV) as a teratogen is a profound challenge to global public health. Molecular diagnosis of infection is straightforward during the 3-week period when patients are viremic. However, serological diagnosis thereafter of historical exposure has been confounded by cross-reactivity. Using high-density peptide arrays that tile the proteomes of a selection of flaviviruses to identify a ZIKV-specific peptide, we established two assays that enable sensitive and specific diagnosis of exposure to ZIKV. These assays may be useful in guiding clinical management of mothers at risk for potential exposure to ZIKV and enable insights into the epidemiology of ZIKV infections.